Real-World Safety of Biologic Agents in Patients With Multiple Comorbidities

Abstract

Patients with inflammatory bowel disease frequently present with multiple comorbid conditions, complicating biologic therapy selection. This real-world observational study assessed the safety profile of biologic agents in patients with significant cardiovascular, metabolic, or renal comorbidities. Data from 610 patients across five European centers were analyzed. Although biologic therapy was generally well tolerated, patients with multiple comorbidities experienced higher rates of infections and treatment discontinuation. Careful monitoring and individualized treatment strategies are essential when managing complex patient populations.